



INDUSTRY

Technology

FOUNDED

November 2021

LOCATION

South Bend, IN

EMPLOYEES

4 FTE

FUNDRAISING

\$5M Seed Extension

VERTICALS

Healthcare/Wellness

PATENTS

Worldwide license to 7+ Issued Utility

Patents (+ CIP)

4+ Patents Pending

CO-FOUNDING LEADERSHIP TEAM

Ray Fraser, CEO

Cassandra Adams, COO

Chris Rauh, CTO

Dr. Rick Snyder, CMO

VITAL VIEW TECHNOLOGIES

EXECUTIVE SUMMARY

Vital View Technologies (VVT) is a medical IoT company that is revolutionizing the world of sensors through state-of-the-art technology that provides decision makers with actionable insights. We bring research in polarization mode dispersion (PMD) to real-world applications by implementing connected solutions to solve industry challenges.

Within Healthcare the most costly chronic disease is heart disease, with Congestive Heart Failure (CHF) creating the largest burden on the US healthcare system, currently costing \$44B annually, and estimated to reach \$90B by 2030. 90% of hospital readmissions from CHF are triggered by a fluid overload event resulting from fluid build-up in the patient's lungs. Current monitoring technologies available are expensive, invasive, or inaccurate but most importantly, do not provide early enough warning for caregivers to take actions that prevent repeated hospitalizations.

Our mission aims to change the short and long-term treatment of chronic illness patients by developing state-of-the-art connected solutions for the hospital-at-home. Our monitoring platform features a proprietary non-contact, noninvasive at-home medical monitor that tracks fluid change over time. This provides early, actionable data to clinicians inform patient care plans and prevent costly hospitalizations.

After securing FDA 510(k) clearance, VVT anticipates early adopters in Accountability Care Organizations with a SOM of \$1.2B. In parallel VVT will conduct real world evidence studies to support payor reimbursement claims. We anticipate receiving reimbursement in 2025 for our at-home system (\$5,000) as well as for the monthly data subscription fee (\$50/mo).

Following reimbursement approval, the Vital View monitor will be prescribed by cardiologist to diagnosed CHF patients which is estimated to reach 8.5M patients in 2030. Other market opportunities are in Chronic Kidney Disease, Liver Disease, and intensive care units for a combined market potential of \$292B.

Vital View Technologies has raised a Seed round of \$1.6M and is currently raising a seed extension round of \$5M to finalize product development, complete clinical studies, and submit FDA 510(k) clearance in Q4 of 2024.

Vital View Technologies, Inc.

1400 E. Angela Blvd. Suite 272 South Bend, Indiana 46617